MIRUM PHARMACEUTICALS INC
NASDAQ: MIRM (Mirum Pharmaceuticals, Inc.)
Last update: 2 hours ago43.45
0.91 (2.14%)
| Previous Close | 42.54 |
| Open | 42.51 |
| Volume | 339,385 |
| Avg. Volume (3M) | 497,863 |
| Market Cap | 2,148,789,248 |
| Price / Earnings (Forward) | 39.68 |
| Price / Sales | 6.00 |
| Price / Book | 9.32 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2025 |
| Profit Margin | -26.10% |
| Operating Margin (TTM) | -24.37% |
| Diluted EPS (TTM) | -1.85 |
| Quarterly Revenue Growth (YOY) | 42.90% |
| Total Debt/Equity (MRQ) | 140.83% |
| Current Ratio (MRQ) | 3.10 |
| Operating Cash Flow (TTM) | 10.32 M |
| Levered Free Cash Flow (TTM) | 18.02 M |
| Return on Assets (TTM) | -8.31% |
| Return on Equity (TTM) | -37.08% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Mirum Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.0 |
| Average | 1.25 |
|
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter “IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.99% |
| % Held by Institutions | 107.07% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Frazier Life Sciences Management, L.P. | 31 Dec 2024 | 6,570,392 |
| Bvf Inc/Il | 31 Dec 2024 | 2,796,513 |
| Eventide Asset Management, Llc | 31 Dec 2024 | 2,606,938 |
| Novo Holdings A/S | 31 Dec 2024 | 1,500,000 |
| Rock Springs Capital Management Lp | 31 Dec 2024 | 1,471,564 |
| Price T Rowe Associates Inc /Md/ | 31 Dec 2024 | 1,422,729 |
| Tang Capital Management Llc | 31 Dec 2024 | 1,237,107 |
| Clearbridge Investments, Llc | 31 Dec 2024 | 907,317 |
| Pictet Asset Management Holding Sa | 31 Dec 2024 | 860,096 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 74.00 (Citizens Capital Markets, 70.31%) | Buy |
| Median | 72.00 (65.71%) | |
| Low | 55.00 (Baird, 26.58%) | Buy |
| Average | 67.00 (54.20%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 48.50 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 28 Feb 2025 | 72.00 (65.71%) | Buy | 47.57 |
| Baird | 27 Feb 2025 | 55.00 (26.58%) | Buy | 46.98 |
| Citizens Capital Markets | 24 Feb 2025 | 74.00 (70.31%) | Buy | 50.95 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |